SI9420017B - Inhibitorji proteaze hiv-a v farmacevtskih kombinacijah za zdravljenje aids-a - Google Patents
Inhibitorji proteaze hiv-a v farmacevtskih kombinacijah za zdravljenje aids-a Download PDFInfo
- Publication number
- SI9420017B SI9420017B SI9420017A SI9420017A SI9420017B SI 9420017 B SI9420017 B SI 9420017B SI 9420017 A SI9420017 A SI 9420017A SI 9420017 A SI9420017 A SI 9420017A SI 9420017 B SI9420017 B SI 9420017B
- Authority
- SI
- Slovenia
- Prior art keywords
- hydroxy
- substituted
- alkyl
- unsubstituted
- aryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Claims (6)
- 4 PATENTNI ZAHTEVKI 1. Kombinacija spojin, kije N-(2(R)-hidroksi-l(S)-indanil)-2(R)-fenilmetil-4(S)-hidroksi-5-(l-(4-(3-piridilmetil)-2(S)-N’-(t-butilkarbamoil)-piperazinil))-pentanamid s 3-([(4,7-dikloro-l,3-benzoksazol-2-il)-metil]amino-5-etil-6-metil-piridin-2(lH)-onom in, opcijsko, z AZT ali ddl ali ddC; pri čemer je spojina N-(2(R)-hidroksi-l(S)-indanil)-2(R)-fenilmetil-4(S)-hidroksi-5-(l-(4-(3-piridilmetil)-2(S)-N’-(t-butilkarbamoil)-piperazinil))-pentanamid po želji v oblik1 farmacevtsko sprejemljive soli.
- 2. Kombinacija spojin, ki je N-(2(R)-hidroksi-l(S)-indanil)-2(R)-fenilmetil-4(S)' hidroksi-5-(l-(4-(3-piridilmetil)-2(S)-N’-(t-butilkarbamoil)-piperazinil))-pentanamid in AZT ali ddl ali ddC; pri čemer je spojina N-(2(R)-hidroksi-l(S)“ indanil)-2(R)-fenilmetil-4(S)-hidroksi-5-(l-(4-(3-piridilmetil)-2(S)-N’-(t-butilkarbamoil)-piperazinil))-pentanamid po želji v obliki farmacevtsko sprejemljive soli.
- 3. Kombinacija spojin, ki je N-(2(R)-hidroksi-l(S)-indanil)-2(R)-fenilmetil-4(S)-hidroksi-5-(l-(4-(3-piridilmetil)-2(S)-N’-(t-butilkarbamoil)-piperazinil))-pentanamid ali farmacevtsko sprejemljiva sol le-tega in analog nukleozida, pri čemer ima omenjeni analog značilno lastnost zaviranja HlV-reverzne transkriptaze.
- 4. Kombinacija spojin, kije (i) katerakoli izmed AZT ali ddl ali ddC v kombinaciji s (ii) spojino s formulo Z R1 X R3kjer je X -OH; Z je -O; Rje vodik ali Cm alkil, R1 in R2 sta neodvisno 1) vodik, 2) -Cm alkil, nesubstituiran ali substituiran z eno ali z več skupinami izmed naslednjih, ki so a) halo, b) hidroksi, c) Cm alkoksi, d) aril, nesubstituiran ali substituiran z eno ali z več skupinami izmed Cm alkila, hidroksi ali arila, e) -W-aril ali-W bertzil, v katerem je W -O-,-S-ali-NH-, f) 5-7 členska cikloalkilna skupina, nesubstituirana ali substituirana z eno ali z več skupinami izmed naslednjih, ki so i) halo, ii) hidroksi iii) Ci-3 alkoksi ali iv) aril, g) heterocikel, nesubstituiran ali substituiran z enim ali z več skupinami izmed hidroksi, Cm alkila, opcijsko substituiranega s hidroksi ali Boc, h) O ii -NH-COCio alkil, i) O II -NH-C-Ci-3 alkil, j) -NH-SOzCm alkil, 3 k) -NRa, l) -COOR ali m) -((CH2)mO)nR, pri čemer je m 2-5, nje nič, 1, 2 ali 3 ali 3) aril, nesubstituiran ali substituiran z eno ali z več skupinami izmed naslednjih, ki so a) halo, b) hidroksi, c) -N02 ali -NR2, d) Cm alkil, e) Ci-3 alkoksi, nesubstituiran ali substituiran z eno ali z več skupinami izmed -OH ali C1-3 alkoksi, f) -COOR, g) O 11 -cnr2, h) -CH2NR2, 0 O II -CH2NHCR, j) -CN, k) -cf3 l) o II -NHCR, m) aril C 1.3 alkoksi, n) aril, k o) -NRS02R, p) -OP(0)(ORx)2 ali q) -R5, kot je definiran spodaj; ali sta R1 in R2 povezana skupaj in tvorita z dušikom, na katerega je R1 vezan, 3- do 10-členski monocikličen ali bicikličen, nasičen obročni sistem, ki sestoji iz dušika na katerega je R1 vezan in iz 2 do 9 ogljikovih atomov in je nesubstituiran ali substituiran z -W-arilom ali ali sta R'in R2 povezana skupaj, tako da tvorita z dušikom, na katerega je R1 vezan, 3- do 10-členski, monocikličen ali bicikličen, nasičen obročni sistem, ki sestoji iz dušika, na katerega je R1 vezan, iz 1 do 8 ogljikovih atomov in enega izmed -N- V-R1 kjer je V odsoten ali O 11 -C-Q- ali -S02-Q-, R1 je definiran kot zgoraj za takrat, ko je R1 neodvisen od R2 in ni vezan na njega, in pri čemer je Q odsoten ali so -O-, -NR- ali heterocikel opcijsko substituirani s Cm alkilom; R3 je benzil, nesubstituiran ali substituiran z enim ali z več (1) hidroksi, (2) C1.3 alkoksi, ki je substituiran z enim ali z več -OH-ali (3)N O ; δ* Rx je Η ali aril; R5 je 1) -VV-iCH^-NRV kjer je W definiran kot zgoraj, m je 2-5 in R6 in R7 sta neodvisno a) vodik b) Ci.<5 alkil, nesubstituiran ali substituiran z eno ali z več skupinami od naslednjih, ki so i) Ci-3 alkoksi, ii) -OH ali iii) -NR2, c) enaka ali različna in povezana skupaj, tako da tvorita 5-7-členski heterocikel, kot morfolino, ki vsebuje do dveh dodatnih heteroatomov, izbranih izmed R O 1 11 -N-, -0-,-S-, -S-, ali -SO2-, pri čemer je heterocikel opcijsko substituiran s C1.4 alkilom ali d) aromatski heterocikel, nesubstituiran ali substituiran z eno ali z več skupinami od naslednjih, ki so i) C1.4 alkil ali ii) -NR2, 2) -(CH2)q-NR6R7, kjer je q 1-5, R6 in R7 pa sta definirana zgoraj, le da R6 in R7 nista H ali nesubstituirani Cm alkil ali 3) benzofuril, indolil, azacikloalkil, azabiciklo C7-11 cikloalkil ali benzopiperidi-nil, nesubstituiran ali substituiran s Cm alkilom; B je odsoten; J1 je -NH-Cm alkil; in J2 jev katerih aril pomeni fenil ali naftil; heterocikel ali heterociklični pomeni stabilen 5- do 7-členski mono- ali bicikličen ali stabilen 7- do 10-členski bicikličen heterocikličen obročni sistem, čigar katerikoli obroč je lahko nasičen ali nenasičen in ki sestoji iz ogljikovih atomov in iz enega ali več heteroatomov, izbranih iz skupine, sestoječe iz N, O in S, in pri čemer sta dušik in žveplo opcijsko oksidirana, dušikov atom pa je lahko opcijsko kvatemiran in pri čemer je vključena katerakoli biciklična skupina, v kateri je katerikoli od zgoraj definiranih heterocikličnih obročev pripojen benzenovemu obroču.
- 5. Kombinacija N-(2(R)-hidroksi-l(S)-indanil)-2(R)-fenilmetil-4(S)-hidroksi-5-(l-(4-(3-piridilmetil)-2(S)-N,-(t-butilkarbamoil)-piperazinil))-pentanamida ali njegove farmacevtsko sprejemljive soli in kateregakoli zdravila, ki ga izberemo izmed naslednjih, ki so: AL-721, rekombinantni humani interferon beta, Acemannan, Cytovene, Ganciclovir, didehidrodeoksitimidin, dideoksinozin, dideoksicitidin, EL-10, trinatrijev fosfono format, Novaprene, pepitna T oktapeptidna sekvenca, zidovudin, Ansamycin LM 427, dekstran sulfat, Virazole Ribavirin, alfa interferon, aciklovir, 3-([(4,7-dikloro-l,3-benzolsazol-2-il)metil]-amino-5-etil-6-metil-piridin-2(lH)-on, 3-[2-(l,3-benzoksazol-2-il)etil]-5-etil-6-metil-piridin-2(lH)-on, AS-101, bropirimin, CL246,738, gama interferon, stimulirajoči faktor kolonije granulocitnih makrofagov, imunostimulans jedrnih HIV delcev, interIevkin-2, intravenski (humani) imuno-globulin, IMREG-1, IMREG-2, imutiol dietil ditio karbamat, interferon alfa-2, metionin-enkefalin, MTP-PE muramil-tripeptid, rekombinantni topni humani CD4, rCD4-IgG hibridi, interferon alfa 2a, SK&F 106528 topni T4, timopentin, tumorje nekrotizirajoči faktor, klindamicin s primakinom, flukonazol, tablete nistatin, Omydil Eflornithine, Piritrexim, pentamidin izetionat (IM & IV), trimetoprim, trimetoprim/sulfa, pentamidin izetionat za vdihavanje, spiramicin, Intraconazole-R51211, trimetreksat, rekombinantni humani eritropoietin, megestrol acetat in totalna umetna prehrana. Farmacevtski sestavek, ki obsega kombinacijo iz kateregakoli zahtevka 1-5 in farmacevtsko sprejemljiv nosilec. Farmacevtski sestavek iz zahtevka 6 za uporabo pri zdravljenju AIDS-a, pri preprečevanju okužbe s HlV-om, pri zdravljenju okužbe s HlV-om ali pri zaviranju HlV-proteaze. &
- 8. Uporaba kombinacije spojin, navedenih v kateremkoli od zahtevkov 1, 2, 3, 4 ali 5 za pripravo zdravila za preprečevanje okužbe s HlV-om, za zaviranje HIV-proteaze ali zdravljenje AIDS-a. Za: Merck & Co., Inc O D Y E T NIC A 24 tM.: i007l)60.ftx-433 70 98
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4072993A | 1993-03-31 | 1993-03-31 | |
PCT/US1994/003209 WO1994022480A1 (en) | 1993-03-31 | 1994-03-24 | Hiv protease inhibitors in pharmaceutical combinations for the treatment of aids |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9420017A SI9420017A (en) | 1996-10-31 |
SI9420017B true SI9420017B (sl) | 2003-12-31 |
Family
ID=21912617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9420017A SI9420017B (sl) | 1993-03-31 | 1994-03-24 | Inhibitorji proteaze hiv-a v farmacevtskih kombinacijah za zdravljenje aids-a |
Country Status (35)
Country | Link |
---|---|
EP (1) | EP0617968B1 (sl) |
JP (1) | JPH08508496A (sl) |
KR (1) | KR100311551B1 (sl) |
CN (1) | CN1090186C (sl) |
AT (1) | ATE230610T1 (sl) |
AU (1) | AU685772B2 (sl) |
BG (1) | BG62083B1 (sl) |
BR (1) | BR9406503A (sl) |
CA (1) | CA2120192A1 (sl) |
CY (1) | CY2326B1 (sl) |
CZ (1) | CZ286412B6 (sl) |
DE (1) | DE69431972T2 (sl) |
DK (1) | DK0617968T3 (sl) |
DZ (1) | DZ1766A1 (sl) |
ES (1) | ES2188604T3 (sl) |
FI (1) | FI954580A0 (sl) |
HK (1) | HK1009248A1 (sl) |
HR (1) | HRP940209B1 (sl) |
HU (1) | HUT74006A (sl) |
IL (1) | IL109166A (sl) |
LV (1) | LV13141B (sl) |
NO (1) | NO953876L (sl) |
NZ (1) | NZ265164A (sl) |
PL (1) | PL310895A1 (sl) |
PT (1) | PT617968E (sl) |
RO (1) | RO118000B1 (sl) |
RU (1) | RU2139052C1 (sl) |
SA (1) | SA94140745B1 (sl) |
SG (1) | SG64366A1 (sl) |
SI (1) | SI9420017B (sl) |
SK (1) | SK279471B6 (sl) |
TW (1) | TW307684B (sl) |
WO (1) | WO1994022480A1 (sl) |
YU (1) | YU49275B (sl) |
ZA (1) | ZA942255B (sl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ288312B6 (en) * | 1993-12-15 | 2001-05-16 | Merck & Co Inc | HIV-protease inhibitors and pharmaceutical preparations in which they are comprised |
UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
US5476874A (en) * | 1994-06-22 | 1995-12-19 | Merck & Co., Inc. | New HIV protease inhibitors |
JPH10507917A (ja) * | 1994-10-25 | 1998-08-04 | メルク エンド カンパニー インコーポレーテッド | Hivプロテアーゼ阻害剤の微生物合成 |
US6689761B1 (en) | 1995-02-01 | 2004-02-10 | Merck & Co., Inc. | Combination therapy for HIV infection |
US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
PE11499A1 (es) * | 1997-05-16 | 1999-03-01 | Procter & Gamble | Tratamiento del hiv y cancer |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
HU9701081D0 (en) * | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
WO2000002862A1 (en) | 1998-07-08 | 2000-01-20 | G.D. Searle & Co. | Retroviral protease inhibitors |
AU6508899A (en) | 1998-10-13 | 2000-05-01 | Du Pont Pharmaceuticals Company | Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
US6462062B1 (en) | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6608096B1 (en) | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6407105B1 (en) | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
MX2007000762A (es) | 2004-07-22 | 2007-04-02 | Ptc Therapeutics Inc | Tienopiridinas para tratamientode hepatitis c. |
RU2520967C1 (ru) * | 2013-02-08 | 2014-06-27 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | СИММЕТРИЧНЫЕ ДИИМИНЫ НА ОСНОВЕ КАМФОРЫ - ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ГРИППА (ШТАММ A/California/07/09 (H1N1)pdm09) |
CN109528747A (zh) * | 2018-12-13 | 2019-03-29 | 中国人民解放军总医院 | 扎西他滨在制备抗菌消炎药物中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06508146A (ja) * | 1991-06-04 | 1994-09-14 | スミスクライン・ビーチャム・コーポレイション | 炭素環および複素環式hivプロテアーゼ抑制剤 |
-
1994
- 1994-03-24 SI SI9420017A patent/SI9420017B/sl not_active IP Right Cessation
- 1994-03-24 CN CN94191671A patent/CN1090186C/zh not_active Expired - Fee Related
- 1994-03-24 RU RU95122135/14A patent/RU2139052C1/ru not_active IP Right Cessation
- 1994-03-24 CZ CZ19952528A patent/CZ286412B6/cs not_active IP Right Cessation
- 1994-03-24 JP JP6522189A patent/JPH08508496A/ja not_active Ceased
- 1994-03-24 NZ NZ265164A patent/NZ265164A/en unknown
- 1994-03-24 BR BR9406503A patent/BR9406503A/pt not_active Application Discontinuation
- 1994-03-24 PL PL94310895A patent/PL310895A1/xx unknown
- 1994-03-24 KR KR1019950704319A patent/KR100311551B1/ko not_active IP Right Cessation
- 1994-03-24 WO PCT/US1994/003209 patent/WO1994022480A1/en active IP Right Grant
- 1994-03-24 HU HU9502860A patent/HUT74006A/hu unknown
- 1994-03-24 SK SK1225-95A patent/SK279471B6/sk unknown
- 1994-03-24 RO RO95-01690A patent/RO118000B1/ro unknown
- 1994-03-28 TW TW083102718A patent/TW307684B/zh active
- 1994-03-29 DK DK94302260T patent/DK0617968T3/da active
- 1994-03-29 SG SG1996008650A patent/SG64366A1/en unknown
- 1994-03-29 ES ES94302260T patent/ES2188604T3/es not_active Expired - Lifetime
- 1994-03-29 DE DE69431972T patent/DE69431972T2/de not_active Expired - Fee Related
- 1994-03-29 AT AT94302260T patent/ATE230610T1/de not_active IP Right Cessation
- 1994-03-29 PT PT94302260T patent/PT617968E/pt unknown
- 1994-03-29 CA CA002120192A patent/CA2120192A1/en not_active Abandoned
- 1994-03-29 EP EP94302260A patent/EP0617968B1/en not_active Expired - Lifetime
- 1994-03-30 AU AU59213/94A patent/AU685772B2/en not_active Ceased
- 1994-03-30 ZA ZA942255A patent/ZA942255B/xx unknown
- 1994-03-30 DZ DZ940030A patent/DZ1766A1/fr active
- 1994-03-30 YU YU15994A patent/YU49275B/sh unknown
- 1994-03-30 HR HR940209A patent/HRP940209B1/xx not_active IP Right Cessation
- 1994-03-30 IL IL10916694A patent/IL109166A/en not_active IP Right Cessation
- 1994-05-31 SA SA94140745A patent/SA94140745B1/ar unknown
-
1995
- 1995-09-20 BG BG100016A patent/BG62083B1/bg unknown
- 1995-09-27 FI FI954580A patent/FI954580A0/fi unknown
- 1995-09-29 NO NO953876A patent/NO953876L/no unknown
-
1998
- 1998-08-12 HK HK98109863A patent/HK1009248A1/xx not_active IP Right Cessation
-
2003
- 2003-05-07 CY CY0300041A patent/CY2326B1/xx unknown
-
2004
- 2004-01-07 LV LVP-04-02A patent/LV13141B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9420017B (sl) | Inhibitorji proteaze hiv-a v farmacevtskih kombinacijah za zdravljenje aids-a | |
JP5227805B2 (ja) | Iap阻害剤とタキサン7の組合せ剤 | |
AU2001281989B2 (en) | Novel heteroaryl derivatives and use thereof as anti-tumour agents | |
AR018175A1 (es) | Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados. | |
CN114057702B (zh) | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 | |
TR200102568T2 (tr) | Amid türevleri. | |
CA2481369A1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
AR039203A1 (es) | Derivados de quinazolina | |
GB1525958A (en) | 2-(heterocyclic substituted alkylsulphinyl)-benzimidazoles and their pharmaceutical compositions | |
RU94027563A (ru) | Соединения-ингибиторы вич протеазы, их использование для лечения спида, форикомпозиция | |
RU2004122926A (ru) | Замещенные производные хиназолина как ингибиторы ауроракиназы | |
TR200102959T2 (tr) | İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri | |
RU99106782A (ru) | N-замещенные индол-3-глиоксиламиды, обладающие противоастматическим, противоаллергическим и иммунодепрессивным/иммуномодуляторным действием, способ их получения, применение, лекарственный препарат и способ его получения | |
AU2001293233A1 (en) | Aza heterocyclic derivatives and their therapeutic use | |
CA2118195A1 (en) | Pharmaceutical composition | |
WO2008141385A1 (en) | Viral polymerase inhibitors | |
KR900015729A (ko) | 흥분성 아미노산 길항제 | |
PL315035A1 (en) | Cyclic amide derivatives as antagonistic substances in respect to neurokinin a | |
TR200000752T2 (tr) | Etkin terkibin kontrollü salınımı için ilaç formülü. | |
FI951858A (fi) | Kinoloni- ja akridonijohdannaisia virtsanpidätyskyvyttömyyden hoidossa | |
RU2001126725A (ru) | Гетероциклические соединения, их промежуточные продукты и ингибиторы эластазы | |
CN105732583B (zh) | 一种治疗脑胶质母细胞瘤的靶向化合物 | |
HUP0201315A2 (hu) | 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények | |
HUP0104469A2 (hu) | Szubsztituált benzo[de]izokinolin-1,3-dion-származékok, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
KR930006024A (ko) | 이미다조 인돌리진 유도체 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
KO00 | Lapse of patent |
Effective date: 20081201 |